Wong K K, Golomb H M, Rowley J, Baker A L, Testa J, Vardiman J
Cancer Genet Cytogenet. 1982 Apr;5(4):281-92. doi: 10.1016/0165-4608(82)90094-2.
In a retrospective analysis, we studied the effects of posttransfusion hepatitis (non-A, non-B) and chromosomal leukemia upon the overall times of adult patients with acute nonlymphocytic leukemia (ANLL). Seventy-two patients treated at the University of Chicago from 1970 to 1981 were evaluable. The complete remission (CR) rate for the entire group of patients was 33%, and the median survival was 246 days. Twenty-eight patients (39%) developed hepatitis, and 42 (61%) did not. The CR rate of the patients with hepatitis was 54%, and the median survival of this group was 615 days. In comparison, the CR rate for those who did not develop hepatitis was 20%, and their median survival was 136 days (p less than 0.0001). The groups were comparable in terms of race, sex, initial hematologic parameters, chromosomal abnormalities, dates of treatment, chemotherapy treatment programs, and French-American-British (FAB) subtype, but the median age of the patients who did not develop hepatitis was higher than that of the others. Patients who had normal karyotypes and who developed hepatitis had the best overall prognosis (median survival of 738 days). Patients with abnormal karyotypes who failed to develop hepatitis had the shortest survival times (median, 124 days). The group of patients who had the longest survival (median, 1130 days) included those over 40 years old, with posttransfusion hepatitis, and with normal karyotypes. The development of posttransfusion hepatitis and the presence of chromosomal abnormalities appear to be important, but opposite, indicators of overall prognosis for patients with ANLL.
在一项回顾性分析中，我们研究了输血后肝炎（非甲非乙型）和染色体白血病对成年急性非淋巴细胞白血病（ANLL）患者总生存时间的影响。对1970年至1981年在芝加哥大学接受治疗的72例患者进行了评估。整个患者组的完全缓解（CR）率为33%，中位生存期为246天。28例患者（39%）发生肝炎，42例（61%）未发生肝炎。发生肝炎患者的CR率为54%，该组中位生存期为615天。相比之下，未发生肝炎患者的CR率为20%，中位生存期为136天（p<0.0001）。两组在种族、性别、初始血液学参数、染色体异常、治疗日期、化疗方案以及法美英（FAB）亚型方面具有可比性，但未发生肝炎患者的中位年龄高于其他患者。核型正常且发生肝炎的患者总体预后最佳（中位生存期738天）。核型异常且未发生肝炎的患者生存时间最短（中位生存期124天）。生存时间最长（中位生存期1130天）的患者组包括40岁以上、患有输血后肝炎且核型正常的患者。输血后肝炎的发生和染色体异常的存在似乎是ANLL患者总体预后的重要但相反的指标。
